Long-term endocrine sequelae after surgery, radiotherapy, and chemotherapy in children with medulloblastoma.
Thirteen children with medulloblastoma, were studied after 2 to 62 months off radiotherapy and chemotherapy with methotrexate and BCNU. Ages at time of study ranged from 2.3 to 15.7 years. Eleven patients, followed for a mean of 22 months, showed a significant decrease of height score, whereas nine patients had deficient growth hormone (GH) response to provocative tests. Clinical pubertal progression was normal in all patients, and three of five girls with advanced pubertal development had menarche. No evidences of gonadotropin disturbances were found in five patients whereas seven had raised basal follicle-stimulating hormone (FSH) level or FSH response to luteinizing hormone-releasing hormone (LH-RH). Abnormalities in thyrotrophin (TSH) secretion were found in 9 of 13 patients. This study shows that poor growth and GH deficiency were frequent in our patients. The high frequency of thyroid disturbances observed point out the need of evaluating thyroid function for adequate replacement therapy. Perhaps modification of adjuvant chemotherapy in the future can diminish drug-induced gonadal damage.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects; D001932:Brain Neoplasms / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D012734:Disorders of Sex Development / Q000209:etiology; D004700:Endocrine System Diseases / Q000209:etiology*; D005260:Female; D006066:Gonads / Q000502:physiology; D006130:Growth Disorders / Q000209:etiology; D013006:Growth Hormone / Q000032:analysis; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D008297:Male; D008527:Medulloblastoma / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects; D013959:Thyroid Diseases / Q000209:etiology; D013960:Thyroid Function Tests
D000970:Antineoplastic Agents; D013006:Growth Hormone